Zhong Hua, Xu Lan, Zhong Ji-Hua, Xiao Fei, Liu Qiang, Huang Hong-Hui, Chen Fang-Yuan
Departments of Hematology and.
Exp Ther Med. 2012 May;3(5):763-770. doi: 10.3892/etm.2012.502. Epub 2012 Mar 2.
It has been found that aberrant expression of microRNAs (miRNAs) is strongly associated with carcinogenesis. In the present study, we investigated the expression of miR-155 and miR-146a in diffuse large B-cell lymphoma (DLBCL) patients (n=90). The expression levels of miR-155 and miR-146a were significantly higher in de novo DLBCL patients. miR-146a expression levels were associated with miR-155, lactate dehydrogenase, β 2 microglobulin, c-myc, International Prognostic Index status and Eastern Cooperative Oncology Group performance status. We found that patients with low miR-155 and miR-146a expression levels achieved a higher complete remission rate, higher overall response rate and longer progression-free survival time. Moreover, a high expression level of miR-155, but not miR-146a, was an independent indicator for chemotherapy protocol selection in our study. Patients with high expression of miR-155 received more survival benefits from rituximab treatment. These data suggest that miR-155 and miR-146a have potential as diagnostic and prognostic markers in DLBCL.
已发现微小RNA（miRNA）的异常表达与癌症发生密切相关。在本研究中，我们调查了弥漫性大B细胞淋巴瘤（DLBCL）患者（n = 90）中miR - 155和miR - 146a的表达情况。初发DLBCL患者中miR - 155和miR - 146a的表达水平显著更高。miR - 146a的表达水平与miR - 155、乳酸脱氢酶、β2微球蛋白、c - myc、国际预后指数状态及东部肿瘤协作组体能状态相关。我们发现miR - 155和miR - 146a表达水平低的患者达到更高的完全缓解率、更高的总缓解率及更长的无进展生存期。此外，在我们的研究中，miR - 155高表达而非miR - 146a高表达是化疗方案选择的独立指标。miR - 155高表达的患者从利妥昔单抗治疗中获得更多生存益处。这些数据表明miR - 155和miR - 146a在DLBCL中具有作为诊断和预后标志物的潜力。
